Cover Image

Biomarkers for predicting immune reconstitution inflammatory syndrome in dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid: A retrospective observational study with a case series

Abstract Background The prognosis of dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid (DPP‐4i‐BP) is variable, with some cases showing spontaneous remission after drug cessation and others showing worsening BP or developing infectious complications, termed infectious immune reconstitut...

Full description

Saved in:

Bibliographic Details
Main Authors:	Seiko Sugiyama (Author), Takenobu Yamamoto (Author), Yumi Aoyama (Author)
Format:	Book
Published:	Wiley, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dramatic deterioration or new‐onset dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid after COVID‐19 vaccination: A possible manifestation of immune reconstitution inflammatory syndrome
by: Midori Sunada, et al.
Published: (2023)

Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome
by: Seiko Sugiyama, et al.
Published: (2020)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
by: Agoritsa Gravani, et al.
Published: (2022)

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
by: Hiroyuki Takama, et al.
Published: (2018)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022)

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
by: Outi Lindgren, et al.
Published: (2019)

Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022)

Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid
by: Chigusa Yamashita, MD, et al.
Published: (2022)

Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions
by: Yumi Aoyama, et al.
Published: (2022)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
by: Hiroshi Kasamatsu, et al.
Published: (2021)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
by: Shoombuatong W, et al.
Published: (2015)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Hiroki Esaki, et al.
Published: (2017)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018)

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus
by: Elisabetta Bigagli, et al.
Published: (2020)

Erythrodermic bullous pemphigoid
by: Mai Endo, et al.
Published: (2021)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
by: Yinqiu Yang, et al.
Published: (2017)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
by: Jong-Mi Seong, et al.
Published: (2021)

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review
by: Xin Jiang, et al.
Published: (2024)

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats
by: Kotaro Takasaki, et al.
Published: (2004)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
by: Capuano A, et al.
Published: (2013)

Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification
by: Danielle K. Nagy, et al.
Published: (2024)

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
by: Rahim K, et al.
Published: (2024)

Bullous Pemphigoid: A Series Of 50 Cases
by: Tatiana Miyuki Iida, et al.
Published: (2024)

Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus
by: Cheng-Yi Wang, et al.
Published: (2023)

An ethnopharmacology study of Indonesian medicinal plants in Gunung Sari village as dipeptidyl peptidase-IV inhibitor
by: Greesty Finotory Swandiny, et al.
Published: (2023)

Design, synthesis and anti-diabetic activity of piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors
by: Swarna Bharathi Kalli, et al.
Published: (2022)

Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
by: Woh Yon Mak, et al.
Published: (2020)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
by: Sibhghatulla Shaikh, et al.
Published: (2021)

Bullous eczema presenting as bullous pemphigoid-like eruption: A case series
by: George Atteh, BS, et al.
Published: (2021)

Bullous pemphigoid
by: Denise Miyamoto, et al.

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
by: David Nash, BHSc, et al.
Published: (2023)

Dipeptidyl peptidase IV inhibitors derived from a mangrove flora Rhizophora mucronata: An in silico approach
by: Selvaraj Gurudeeban, et al.
Published: (2012)

The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
by: Olesya M. Taylor, PharmD, BCPS, et al.
Published: (2020)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
by: Permsuwan U, et al.
Published: (2016)

Coumarin Derivatives Act as Novel Inhibitors of Human Dipeptidyl Peptidase III: Combined In Vitro and In Silico Study
by: Dejan Agić, et al.
Published: (2021)

Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
by: Seung Hee Choi, et al.
Published: (2017)

Gliptin-Associated Bullous Pemphigoid - A Series of 3 Cases
by: Prajesh K. Bhunya, et al.
Published: (2024)

Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach
by: Ipseeta Ray Mohanty, et al.
Published: (2017)